Aprea Therapeutics (NASDAQ:APRE) Trading Down 2.5% – What’s Next?

Posted by Tech Dows on Mar 18th, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report)’s share price was down 2.5% during mid-day trading on Monday . The stock traded as low as $2.34 and last traded at $2.34. Approximately 10,321 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 18,909 shares. The stock had previously closed at $2.40.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Get Our Latest Report on APRE

Aprea Therapeutics Price Performance

The firm’s fifty day moving average price is $3.30 and its 200-day moving average price is $3.30. The firm has a market capitalization of $12.72 million, a P/E ratio of -0.83 and a beta of 0.82.

Institutional Trading of Aprea Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $43,000. LPL Financial LLC acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $53,000. Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $116,000. Finally, Stonepine Capital Management LLC lifted its stake in Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after purchasing an additional 12,047 shares during the last quarter. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.